Japanese scientists are set to kick off the world’s first clinical trials of “tooth regrowth medicine” at the Kyoto University Hospital, The Mainichi reports.
Researchers from the Japanese startup Toregem Biopharma are planning to enroll patients who were born missing some or all of their teeth from birth, a condition called congenital anodontia, for the trials.
The patients will receive an antibody treatment that deactivates a protein called USAG-1, believed to stop “tooth buds,” which most people have, from developing into either baby or permanent teeth.
Comments are closed.